PODD Stock Analysis — Insulet
Sector: Medical Devices
AI Verdict
Insulet trades at a fair multiple for its expected 19.0% EPS growth, but after a -53.40% drop, the moat around Omnipod needs to deliver real user stickiness to justify even a sector-average price.
Competitive Moat
Insulet's Omnipod insulin delivery system is a tubeless, wearable patch pump that reduces hassle for diabetics, creating high switching costs for users accustomed to its convenience. Its moat comes from proprietary device design, FDA approvals, and a growing installed user base that faces friction in changing to alternatives.
Summary
Omnipod's unique wearable insulin pump design is the key differentiator in a market dominated by legacy tubed pumps.
Where It Stands
The stock is down -53.40% over the past year, trades at 22.6x next year's earnings (just above the healthcare sector median of 22x), and its RSI of 35.4 signals shares are near oversold territory.
Key Metrics
- RSI: 35.4 — Near Oversold
- Trailing P/E: 26.9x
- Forward P/E: 22.6x
- PEG Ratio: 1.38
- Earnings Growth: +0.2%
- Revenue Growth: +0.3%
- Market Cap: $10.0B
- 1-Year Return: -53.40%
- 52-Week High: $354.88
- 52-Week Low: $126.40
Analyst Consensus
27 Buy · 6 Hold · 0 Sell (33 analysts)
Bull Case
With forward EPS expected to grow 19.0% and a forward P/E of 22.6x, you're paying a fair price for double-digit earnings growth if Omnipod adoption continues.
Bear Case
If the P/E falls from 22.6x to the sector median of 22x, that's a 2.7% downside, and the -53.40% one-year return shows how quickly sentiment can turn if growth disappoints.
Catalyst to Watch
Watch for FDA approvals or new product launches — a positive regulatory outcome or strong uptake of next-gen Omnipod would support the growth story.